Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV_IN) trial

References

• Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(sup3):21–26.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Alvarez-Pasquin M-J, Bijl M. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3:109–120.
   PubMedGoogle Scholar
• Chen S-Y, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–334.
   PubMed Web of Science ®Google Scholar
• Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000–2012. BMJ Open. 2018;8(6):e020528.
   PubMed Web of Science ®Google Scholar
• Forbes HJ, Bhaskaran K, Thomas SL. Quantification of risk factors for herpes zoster: population based case–control study. BMJ. 2014;348:g2911.
   Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–280.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833-e004833.
   PubMed Web of Science ®Google Scholar
• Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4(1):108–115.
   PubMed Web of Science ®Google Scholar
• Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant. 2007;7(4):741–747.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Itzler RF, Wollan PC, et al. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc. 2009;84(9):787–794.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37.
   PubMed Web of Science ®Google Scholar
• Zostavax (Zoster vaccine live). Package insert. Kenilworth, NJ, USA: Whitehouse Station, NJ. Merck and Co., Inc.; 2009.
   Google Scholar
• Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20(2):285–287.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–526.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Shingrix. [ cited 2019 Oct 28]. Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm581491.htm
   Google Scholar
• Eberhardson M, Hall S, Papp KA, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis. 2017;65(7):82–1174.
   Web of Science ®Google Scholar
• Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208(9):1375–1385.
   PubMed Web of Science ®Google Scholar
• Parrino J, McNeil SA, Lawrence SJ, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 2017;35(14):1764–1769.
   PubMed Web of Science ®Google Scholar
• Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–133.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Mullane KM, Boeckh MJ, et al. A phase III, double-blind, randomized, placebo-controlled, multicenter clinical trial to study the safety, tolerability, efficacy, and immunogenicity of inactivated Vzv Vaccine (ZVIN) in recipients of autologous hematopoietic cell transplants (Auto-Hcts). Biol Blood Marrow Transplant. 2017;23(3):S24–S5.
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.
   PubMed Web of Science ®Google Scholar
• Desmond RA, Weiss HL, Arani RB, et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage. 2002;23(6):510–516.
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–666.
   Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–1736.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Gnann JW Jr., Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(1 Suppl 1):S37–44.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster. PharmacoEconomics. 2007;25(2):155–169.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
   PubMed Web of Science ®Google Scholar
• van Agthoven M, Segeren CM, Buijt I, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer. 2004;40(8):1159–1169.
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen MB, Cabases JM, et al. EQ-5D population norms - national surveys. In: Szende A, Janssen MB, Cabases JM, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014.148–152
   Google Scholar
• Fryback DG, Dunham NC, Palta M, et al. U.S. norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162–1170.
   PubMed Web of Science ®Google Scholar
• Conner-Spady BL, Cumming C, Nabholtz JM, et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant. 2005;36(3):251–259.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care. 2005;43(3):221–228.
   PubMed Web of Science ®Google Scholar
• Mao J, McPheeters JT, Zhang D, et al. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant. Curr Med Res Opin. 2018;34(4):741–749.
   Web of Science ®Google Scholar
• Li Q, Chen SY, Burstin SJ, et al. Cost of herpes zoster in patients with selected immune-compromised conditions in the United States. Open Forum Infect Dis. 2016;3(2):ofw067.
   PubMed Web of Science ®Google Scholar
• Johnson BH, Palmer L, Gatwood J, et al. Healthcare resource utilization and costs associated with herpes zoster in the US. J Med Econ. 2016;19(10):928–935.
   PubMed Web of Science ®Google Scholar
• White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27:781–792.
   PubMed Web of Science ®Google Scholar
• Palmer L, White RR, Johnson BH, et al. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant. Transplantation. 2014;97(11):1178–1184.
   PubMed Web of Science ®Google Scholar
• Meyers JL, Candrilli SD, Rausch DA, et al. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018;36(45):6810–6818.
   PubMed Web of Science ®Google Scholar
• Curran D, Hunjan M, El Ghachi A, et al. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. 2019;9(8):e023502.
   PubMed Web of Science ®Google Scholar
• Friesen KJ, Chateau D, Falk J, et al. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infect Dis. 2017;17(1):69.
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38–47.
   PubMed Web of Science ®Google Scholar
• Taieb V, Schwarzbard J, Butt T, et al. The epidemiological and cost burden of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in the UK. Value Health. 2015;18(7):A589.
   Web of Science ®Google Scholar
• Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
   Web of Science ®Google Scholar